Integrated Biopharma Inc Revenue Growth Rates (INBP), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Integrated Biopharma Inc  (INBP)
 

INBP's Revenue Growth by Quarter and Year

Integrated Biopharma Inc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/INBP/growth
https://api.csimarket.com/api/v1/companies/INBP/fundamentals
https://api.csimarket.com/api/v1/companies/INBP/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
INBP Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter June -
3rd Quarter March -
2nd Quarter December -
1st Quarter September 9.91
FY 9.91

INBPs Annual Revenue
Integrated Biopharma Inc's Revenue in the fiscal year 2026 $ 43.87 millions
Integrated Biopharma Inc's Revenue in the fiscal year 2025 $ 53.56 millions
Integrated Biopharma Inc's Revenue in the fiscal year 2024 $ 49.88 millions
Integrated Biopharma Inc's Revenue in the fiscal year 2023 $ 50.06 millions
Integrated Biopharma Inc's Revenue in the fiscal year 2022 $ 56.25 millions




INBP Revenue first quarter 2026 Y/Y Growth Comment
Integrated Biopharma Inc reported decline in Revenue in the first quarter 2026 by -17.53% to $ 9.91 millions, from the same quarter in 2025.
The contraction in the first quarter 2026 Integrated Biopharma Inc's Revenue compares unfavorably to the Company's average Revenue growth of 0.17%.

Looking into first quarter 2026 results within Major Pharmaceutical Preparations industry 120 other companies have achieved higher Revenue growth. While Integrated Biopharma Inc' s Revenue fall of -17.53% ranks overall at the positon no. 2606 in the first quarter 2026.


INBP Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter June -
3rd Quarter March -
2nd Quarter December -
1st Quarter September -17.53 %
FY   -

Financial Statements
Integrated Biopharma Inc's first quarter 2026 Revenue $ 9.91 millions INBP's Income Statement
Integrated Biopharma Inc's first quarter 2025 Revenue $ 12.02 millions Quarterly INBP's Income Statement


INBP Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter June -
3rd Quarter March -
2nd Quarter December -
1st Quarter September 1.15 %
FY (Year on Year)   -


Back to INBP Growth rate Comparisons >> Back to INBP Growth rate Comparisons >>


Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #121
Healthcare Sector #374
Overall #2606

Revenue Y/Y Growth Statistics
High Average Low
23.23 % 0.17 % -32.74 %
(Dec 31 2016)   (Sep 30 2014)
Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #121
Healthcare Sector #374
Overall #2606
Revenue Y/Y Growth Statistics
High Average Low
23.23 % 0.17 % -32.74 %
(Dec 31 2016)   (Sep 30 2014)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Integrated Biopharma Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
257.72 % 4.67 % -100 %
(Jun 30 2012)  


INBP's I. Quarter Q/Q Revenue Comment
Integrated Biopharma Inc achieved in the I. Quarter 2026 below company average Revenue growth of 1.15% quarter on quarter, to $ 9.91 millions.

I. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -16.93% in the I. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 81 other companies have achieved higher Revenue quarter on quarter growth. While Integrated Biopharma Inc's Revenue growth quarter on quarter, overall rank is 1659.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #82
Healthcare Sector #222
Overall #1659
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #82
Healthcare Sector #222
Overall #1659
Revenue Q/Q Growth Statistics
High Average Low
257.72 % 4.67 % -100 %
(Jun 30 2012)  


INBP's I. Quarter Q/Q Revenue Comment
Integrated Biopharma Inc achieved in the I. Quarter 2026 below company average Revenue growth of 1.15% quarter on quarter, to $ 9.91 millions.

I. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -16.93% in the I. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 81 other companies have achieved higher Revenue quarter on quarter growth. While Integrated Biopharma Inc's Revenue growth quarter on quarter, overall rank is 1659.


Integrated Biopharma Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 42.57
Y / Y Revenue Growth (TTM) -20.53 %
Year on Year Revenue Growth Overall Ranking # 1792
Seqeuential Revenue Change (TTM) -9.89 %
Seq. Revenue Growth (TTM) Overall Ranking # 2606


Cumulative Revenue growth Comment
Integrated Biopharma Inc's cumulative 12 months Revenue continue to fall, but on the faster rate at -20.53% year on year, at Jun 30 2026 compare to the -11.5% decrease at Mar 31 2026. If the Integrated Biopharma Inc's fiscal year would end at Jun 30 2026, annual Revenue would be $43 millions.

In the Healthcare sector 280 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 922 to 1792.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 121
Healthcare Sector # 281
Overall # 1792

Revenue TTM Y/Y Growth Statistics
High Average Low
23.23 %
 0.17 %
-32.74 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 121
Sector # 374
S&P 500 # 2606
Cumulative Revenue growth Comment
Integrated Biopharma Inc's cumulative 12 months Revenue continue to fall, but on the faster rate at -20.53% year on year, at Jun 30 2026 compare to the -11.5% decrease at Mar 31 2026. If the Integrated Biopharma Inc's fiscal year would end at Jun 30 2026, annual Revenue would be $43 millions.

In the Healthcare sector 280 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 922 to 1792.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 121
Healthcare Sector # 281
Overall # 1792

Revenue TTM Y/Y Growth Statistics
High Average Low
23.23 %
0.17 %
-32.74 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 121
Sector # 374
S&P 500 # 2606




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
INBP's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Viatris Inc -0.28%$ -0.277 millions
Zoetis Inc -0.38%$ -0.375 millions
Pfizer Inc-0.43%$ -0.426 millions
Standard Biotools Inc -0.51%$ -0.508 millions
Lucid Diagnostics Inc -0.66%$ -0.661 millions
Globus Medical Inc -0.69%$ -0.693 millions
Conmed Corporation-0.70%$ -0.701 millions
Surgery Partners Inc -0.75%$ -0.755 millions
Myriad Genetics Inc -1.03%$ -1.025 millions
Lensar Inc -1.29%$ -1.292 millions
Fortrea Holdings Inc -1.40%$ -1.397 millions
Immunocore Holdings Plc-1.42%$ -1.419 millions
Pacira Biosciences inc -1.59%$ -1.595 millions
Organon and Co -1.75%$ -1.748 millions
Teva Pharmaceutical Industries Limited-1.90%$ -1.897 millions
Skinhealth Systems Inc -2.07%$ -2.071 millions
Charles River Laboratories International inc -2.20%$ -2.201 millions
Inogen Inc -2.40%$ -2.399 millions
Novavax inc -3.05%$ -3.048 millions
Seer Inc -3.14%$ -3.139 millions
Teladoc Health Inc -3.41%$ -3.406 millions
Scientific Industries Inc -3.50%$ -3.504 millions
Cg Oncology Inc -3.72%$ -3.721 millions
Treace Medical Concepts Inc -3.91%$ -3.905 millions
Sarepta Therapeutics Inc -4.51%$ -4.509 millions
Pacific Health Care Organization Inc-4.69%$ -4.689 millions
Tela Bio Inc -5.06%$ -5.058 millions
Perrigo Company Plc-5.22%$ -5.225 millions
Heron Therapeutics Inc -5.49%$ -5.493 millions
Milestone Scientific Inc -5.95%$ -5.948 millions


About Integrated Biopharma Inc Revenue Growth Rates (INBP), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Integrated Biopharma Inc (CIK 1016504).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001437749-26-036725
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Integrated Biopharma Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.